Home  |  Contact

UniProtKB/Swiss-Prot Q08357: Variant p.His502Gln

Sodium-dependent phosphate transporter 2
Gene: SLC20A2
Variant information

Variant position:  502
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Histidine (H) to Glutamine (Q) at position 502 (H502Q, p.His502Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and polar.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In IBGC1.
Any additional useful information about the variant.



Sequence information

Variant position:  502
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  652
The length of the canonical sequence.

Location on the sequence:   EVHLLFHFLQVLTACFGSFA  H GGNDVSNAIGPLVALWLIYK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYK

Mouse                         EVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYQ

Rat                           EVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYK

Bovine                        EVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYE

Cat                           EVHLLFHFLQVLTACFGSFAHGGNDVSNAIGPLVALWLIYE

Xenopus laevis                QVHLLFHFLQILTACFGSFAHGGNDVSNAIGPLVALWLIYQ

Xenopus tropicalis            EVHLLFHFLQILTACFGSFAHGGNDVSNAIGPLVALWLIYE

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 652 Sodium-dependent phosphate transporter 2
Transmembrane 483 – 503 Helical
Mutagenesis 506 – 506 D -> N. Impairs phosphate transport; no effect on retroviral receptor function.


Literature citations

Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification.
Hsu S.C.; Sears R.L.; Lemos R.R.; Quintans B.; Huang A.; Spiteri E.; Nevarez L.; Mamah C.; Zatz M.; Pierce K.D.; Fullerton J.M.; Adair J.C.; Berner J.E.; Bower M.; Brodaty H.; Carmona O.; Dobricic V.; Fogel B.L.; Garcia-Estevez D.; Goldman J.; Goudreau J.L.; Hopfer S.; Jankovic M.; Jauma S.; Jen J.C.; Kirdlarp S.; Klepper J.; Kostic V.; Lang A.E.; Linglart A.; Maisenbacher M.K.; Manyam B.V.; Mazzoni P.; Miedzybrodzka Z.; Mitarnun W.; Mitchell P.B.; Mueller J.; Novakovic I.; Paucar M.; Paulson H.; Simpson S.A.; Svenningsson P.; Tuite P.; Vitek J.; Wetchaphanphesat S.; Williams C.; Yang M.; Schofield P.R.; de Oliveira J.R.; Sobrido M.J.; Geschwind D.H.; Coppola G.;
Neurogenetics 14:11-22(2013)
Cited for: VARIANTS IBGC1 GLN-382; GLN-502; LEU-568 AND LEU-601;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.